Nanoliter‐scale cell assays for drug development
2021
Karlsruhe Institute of Technology (KIT), Eggenstein‐Leopoldshafen, Germany(1)
Mannheim University of Applied Sciences, Mannheim, Germany(2)
Mannheim University of Applied Sciences, Mannheim, Germany(2)
In pharmaceutical research and development, cell‐based assays are primarily used with a readout that relies on fluorescence‐based and other label‐dependent techniques for the analysis of different cellular processes. Superhydrophobic–hydrophilic droplet microarrays (DMA) and matrix‐assisted laser desorption/ionization (MALDI) mass spectrometry (MS) have recently emerged as key technologies for miniaturized high‐throughput cell assays and for label‐free molecular high‐content drug profiling, respectively. Here, nanoliter‐scale cell assays are integrated on DMAs with MALDI–MS imaging (MALDI–MSI) approaches to a droplet microarray–mass spectrometry imaging (DMA–MSI) platform. This platform is a valuable complement to high throughput cell‐based assays technologies.
Fast nanoliter‐scale cell assays using droplet microarray–mass spectrometry imaging
Pavel A. Levkin(1), Carsten Hopf(2)
Added on: 05-11-2021
[1] https://onlinelibrary.wiley.com/doi/10.1002/adbi.202000279[2] https://www.drugtargetreview.com/news/86265/nanolitre%e2%80%90scale-cell-assays-developed-with-droplet-microarray-mass-spec/?utm_source=Email+marketing&utm_medium=email&utm_campaign=DTR+-+Industry+Insight+-+Ncardia+-+Assays+-+23.04.21&utm_term=Learn+more+about+assay+development+in+our+latest+industry+insight&utm_content=https%3a%2f%2femails.drugtargetreview.com%2frussellpublishinglz%2f&gator_td=lwFkGx6%2fagn8PTRT2P1gkljNovtJNTuVKaURwzFqfo84BDiFriftbL4FqgRnnh0tKsOXsArCTuCxXvS1IYZyZLiGrMEYujhxAMbRq0ysB6%2fqsqS1WPM82MdLIFCfxSQB3peEiZPFnSWkErBYH66ohKy735uST3mgOUsxLOj%2bgOL4xSoQomgeBIOYHKZIbx%2fKSlrR8q8E4wb1ir3Z0fyU7Sdi40jK3CZXO3aex%2fDHBpbhmGga0bW%2bu3nh%2bqOjVBTt
